| Date | Name | Title | Type | Security | Shares | Price | Value | Ownership | Reported |
| 10/03/2023 | BAKER BROS. ADVISORS LP | Director | Purchase | Common Stock Warrant (right to buy) | 125.4k | $0.00 | $12.5 | See Footnotes | 10/03/2023 |
| 10/03/2023 | BAKER BROS. ADVISORS LP | Director | Purchase | Common Stock Warrant (right to buy) | 1.5M | $0.00 | $152.3 | See Footnotes | 10/03/2023 |
| 03/01/2023 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sale | Common Stock | 100 | $276.19 | $27.6k | | 02/28/2023 |
| 03/01/2023 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Exercise | Stock Option (Right to Buy) | 5k | $87.92 | $439.6k | | 02/28/2023 |
| 03/01/2023 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sale | Common Stock | 1.3k | $275.53 | $358.2k | | 02/28/2023 |
| 03/01/2023 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sale | Common Stock | 1.7k | $274.57 | $459.1k | | 02/28/2023 |
| 03/01/2023 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sale | Common Stock | 1.9k | $273.44 | $527.2k | | 02/28/2023 |
| 02/28/2023 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sale | Common Stock | 900 | $271.03 | $243.9k | | 02/28/2023 |
| 02/28/2023 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sale | Common Stock | 4.1k | $272.30 | $1.1M | | 02/28/2023 |
| 02/28/2023 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Exercise | Stock Option (Right to Buy) | 5k | $87.92 | $439.6k | | 02/28/2023 |
| 01/17/2023 | Levy Richard S | Director | Sale | Common Stock | 100 | $285.28 | $28.5k | | 01/17/2023 |
| 01/17/2023 | Levy Richard S | Director | Sale | Common Stock | 400 | $287.08 | $114.8k | | 01/17/2023 |
| 01/17/2023 | Levy Richard S | Director | Sale | Common Stock | 300 | $288.91 | $86.7k | | 01/17/2023 |
| 01/17/2023 | Levy Richard S | Director | Sale | Common Stock | 1.6k | $290.36 | $464.6k | | 01/17/2023 |
| 01/17/2023 | Levy Richard S | Director | Sale | Common Stock | 3.3k | $291.66 | $969.8k | | 01/17/2023 |
| 01/17/2023 | Levy Richard S | Director | Sale | Common Stock | 5.2k | $292.68 | $1.5M | | 01/17/2023 |
| 01/17/2023 | Levy Richard S | Director | Sale | Common Stock | 3.5k | $293.54 | $1M | | 01/17/2023 |
| 01/17/2023 | Levy Richard S | Director | Sale | Common Stock | 5.2k | $294.68 | $1.5M | | 01/17/2023 |
| 01/17/2023 | Levy Richard S | Director | Sale | Common Stock | 2.3k | $295.45 | $686.9k | | 01/17/2023 |
| 01/17/2023 | Levy Richard S | Director | Sale | Common Stock | 500 | $296.68 | $148.3k | | 01/17/2023 |
| 01/17/2023 | Levy Richard S | Director | Exercise | Stock Option (Right to buy) | 12.5k | $105.08 | $1.3M | | 01/17/2023 |
| 01/17/2023 | Levy Richard S | Director | Exercise | Stock Option (Right to Buy) | 10k | $100.45 | $1M | | 01/17/2023 |
| 01/16/2023 | Howarth Alex G. | CFO | Grant | Common Stock | 15k | $0.00 | $0 | | 01/16/2023 |
| 01/16/2023 | Taub Rebecca | Pres., R&D, and CMO | Grant | Common Stock | 20k | $0.00 | $0 | | 01/16/2023 |
| 01/16/2023 | FRIEDMAN PAUL A | CEO | Grant | Common Stock | 26.7k | $0.00 | $0 | | 01/16/2023 |
| 01/16/2023 | Sukhija Remy | Chief Commercial Officer | Grant | Common Stock | 15k | $0.00 | $0 | | 01/16/2023 |
| 01/16/2023 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Grant | Common Stock | 5.7k | $0.00 | $0 | | 01/16/2023 |
| 01/16/2023 | Lynch Brian Joseph | SVP and General Counsel | Grant | Common Stock | 15k | $0.00 | $0 | | 01/16/2023 |
| 01/03/2023 | Lynch Brian Joseph | SVP and General Counsel | Sale | Common Stock | 829 | $285.15 | $236.4k | | 01/03/2023 |
| 01/03/2023 | Lynch Brian Joseph | SVP and General Counsel | Sale | Common Stock | 2k | $285.74 | $582.3k | | 01/03/2023 |
| 01/03/2023 | Lynch Brian Joseph | SVP and General Counsel | Sale | Common Stock | 400 | $286.62 | $114.6k | | 01/03/2023 |
| 01/03/2023 | Lynch Brian Joseph | SVP and General Counsel | Sale | Common Stock | 100 | $287.86 | $28.8k | | 01/03/2023 |
| 01/03/2023 | Lynch Brian Joseph | SVP and General Counsel | Exercise | Stock Option (Right to Buy) | 13k | $91.79 | $1.2M | | 01/03/2023 |
| 01/03/2023 | Lynch Brian Joseph | SVP and General Counsel | Sale | Common Stock | 600 | $277.91 | $166.7k | | 01/03/2023 |
| 01/03/2023 | Lynch Brian Joseph | SVP and General Counsel | Sale | Common Stock | 400 | $279.10 | $111.6k | | 01/03/2023 |
|